India, Aug. 21 -- Ascelia Pharma AB (publ) (ACE.ST), a biotech company, announced on Thursday financial results for the first half year, and registered significantly reduced losses as the company faced challenges in advancing its lead drug candidate.
The Swedish company is focused on developing novel drugs for orphan cancer indications. Currently in the pipeline are Orviglance, a contrast agent used for MR-imaging the liver while diagnosing lesions or cancer metastases; and Oncoral, a formulation of irinotecan used for difficult-to-treat cancers, including gastric cancer.
Q2 Financial Results:
The company's net loss shrunk to SEK 12.1 million in the first half of 2026, nearly half of the SEK 23.0 million reported in the same period of 20...